Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies
This partnership aims to address the growing demand for high-quality diagnostics in metropolitan areas
Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats
Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio
Combined strength of two brands across 11 states to elevate patient care delivery and access to doctors
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
Subscribe To Our Newsletter & Stay Updated
